Bristol-Myers Squibb Company and CytomX Therapeutics, Inc., a biopharma company developing investigational Probody therapeutics to treat cancer, have expanded their 2014 strategic collaboration to discover therapies that will include as many as eight additional targets using CytomX’s Probody platform. Probody therapeutics are designed to leverage unique conditions in the tumor microenvironment to enhance tumor-targeting features of an antibody and reduce drug activity in healthy tissues. Pro...